FINWIRES · TerminalLIVE
FINWIRES

市场动态:三菱重工调整燃气轮机生产线以应对人工智能驱动的需求

By

-- 据《日经新闻》周四报道,三菱重工(TYO:7011)正在对其燃气轮机生产进行全面改革,以提高产量、缩短制造时间并限制资本支出,以应对高耗能人工智能数据中心不断增长的需求。 报道称,三菱重工社长伊藤荣作正在位于日本西部高砂机械制造厂领导一项名为“创新全面优化”的项目。该项目有超过100名员工参与,对采购、组装、测试和设计等1000多个流程进行了审查。 此举旨在提高燃气轮机联合循环系统的效率,并减少不断增长的订单积压。报道称,截至2026年3月,三菱重工能源系统部门的订单额增长约40%,达到3.6万亿日元。 该公司正在通过分离不同型号燃气轮机的装配线并减少设备更换次数来简化生产流程。报道称,三菱重工的目标是在有限的额外投资下,实现约30%的产量增长。 报道称,这家日本制造商计划投资约500亿日元用于涡轮机产能扩张,低于其竞争对手GE Vernova和西门子能源公布的扩张计划。 (市场动态新闻来源于与全球市场专业人士的对话。这些信息据信来自可靠来源,但可能包含传闻和推测。准确性无法保证。)

Related Articles

Asia

StarHub's Net Attributable Profit Falls 81% in Q1

StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.

$SGX:CC3
Asia

Meesho Narrows Consolidated Loss in Fiscal Q4

Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.

$BOM:544632$NSE:MEESHO
Asia

Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug

Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.

$SHE:000661